Archivos de Medicina最新文献

{"title":"Anemia en enfermedad renal cronica","authors":"Adolfo Pertuz-Pinzón, Carlos Ismael-Garcia, Cristian Muñoz-Gómez, Jorge-Eduardo Rico-Fontalvo, Rodrigo Daza-Arnedo, Nehomar Pájaro-Galvis, J. Coronado-Daza, Christian Pérez-Calvo, Isabella Uparella-Gulfo, Oscar Vicente Vergara Serpa, Andrea Pestana-Mir","doi":"10.36648/1698-9465.21.17.1462","DOIUrl":"https://doi.org/10.36648/1698-9465.21.17.1462","url":null,"abstract":"espanolLa anemia es una patologia comun entre los pacientes con enfermedad renal cronica (ERC), siendo la base de muchos de los sintomas asociados con una funcion renal reducida que se asocia con un aumento de la mortalidad y las hospitalizaciones. La anemia es dos veces mas prevalente en personas con ERC que en la poblacion general, aumentando su prevalencia, cuanto mas avanzado se encuentra el estadio de la ERC. La fisiopatologia de la anemia en este grupo de pacientes se caracteriza por una disminucion en la produccion de globulos rojos, dada por una disminucion en la produccion de eritropoyetina que normalmente es producida por los fibroblastos intersticiales en la corteza renal, pero a pesar de ello, el problema principal parece ser la falta de aumento de la produccion de en respuesta a disminucion en las concentraciones de hemoglobina. Los pacientes con anemia deben evaluarse independiente de la etapa de la ERC en la que se encuentren para identificar cualquier proceso reversible que este contribuyendo a la anemia, asi mismo, los pacientes con ERC quienes no presentan un sindrome anemico conocido, se les debe hacer un analisis paraclinico multivariado cuando este clinicamente indicado como en la presencia de astenia, adinamia, disnea, taquicardia, entre otros sintomas asociados. las principales opciones terapeuticas para la anemia van a depender de la gravedad y la causa subyacente de la misma, y que estas opciones terapeuticas incluyen el uso de elementos que van desde el hierro, hasta agentes estimulantes de la eritropoyesis y en raras ocasiones, transfusiones de globulos rojos. EnglishAnemia is a common pathology among patients with chronic kidney disease (CKD), being the basis for many of the symptoms associated with reduced kidney function that is associated with increased mortality and hospitalizations. Anemia is twice more prevalent in people with CKD than in the general population, its prevalence increasing the more advanced the stage of CKD is. The pathophysiology of anemia in this group of patients is characterized by a decrease in the production of red blood cells, given by a decrease in the production of erythropoietin that is normally produced by interstitial fibroblasts in the renal cortex, but despite this, the main problem appears to be the lack of increased production of in response to decreased hemoglobin concentrations. Patients with anemia should be evaluated regardless of the stage of CKD they are in to identify any reversible process that is contributing to anemia, likewise, patients with CKD who do not present a known anemic syndrome, should undergo a multivariate paraclinical analysis when clinically indicated, such as in the presence of asthenia, adynamia, dyspnea, tachycardia, among other associated symptoms. The main therapeutic options for anemia will depend on the severity and underlying cause of the anemia, and that these therapeutic options include the use of elements ranging from iron, to erythropoiesisstimul","PeriodicalId":44458,"journal":{"name":"Archivos de Medicina","volume":"17 1","pages":"1"},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69690777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factores Asociados al Tiempo de Atenciandoacute;n de Pacientes con Diagnandoacute;stico de Iamcest Sometidos a Terapia de Reperfusiandoacute;n en dos Clandiacute;nicas en Ibaguandeacute;","authors":"ra Cardona-Moica, Yizeth Muñoz-Sierra, David Bracho-Navarro, German Augusto-Molina, Nehomar Pájaro-Galvis, Jorge-Eduardo Rico-Fontalvo, Rodrigo Daza-Arnedo, Mayralej, ra Ahumada-Blanco, Dagoberto Serpa-Díaz, Luis Díaz-Rosales, Tomás Acosta","doi":"10.36648/1698-9465.17.1.1460","DOIUrl":"https://doi.org/10.36648/1698-9465.17.1.1460","url":null,"abstract":"Cardiovascular diseases are the leading cause of death worldwide and their management implies an early diagnosis and early coronary reperfusion. In Colombia, the department of Tolima registers the highest death rate from this cause, therefore the objective of the study is to analyze the factors associated with the care time of patients with STEMI undergoing reperfusion therapy in two IPS in the city. This study was conducted in Ibague between 2016 and 2017, longitudinal, analytical, retrospective from time to event. A review of medical records was carried out and of the total of 2755 catheterizations performed during this period, 126 were selected with STEMI, analyzing sociodemographic and clinical conditions of each of the patients. For the analysis of care times, 49 patients who were admitted to the institution from the emergency service were studied. As results, it was found that the average age was 63 years, 71.4% were men. The most prevalent comorbidities were hypertension, dyslipidemia and DM-2. No patient received prehospital medical care. Median gate time - EKG was 27 minutes, gate - needle 75 minutes, and gate - balloon 26 hours. It is concluded that it is necessary to carry out similar studies to know the Latin American statistics since most of the interventions carried out are not within the optimal times established in the international guidelines. Gate time - EKG less than 10 minutes was achieved in 35% of cases. 80% of the patients consulted the window for thrombolysis and only 39% received fibrinolysis in less than 60 minutes; 6.1% were taken to ICCP in less than 90 minutes. With the availability of the hemodynamic unit, a reduction in attention times was achieved compared to the consultation during hours without its availability (p value: 0.033).","PeriodicalId":44458,"journal":{"name":"Archivos de Medicina","volume":"17 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69690235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sandiacute;ndrome de DRESS, Reacciandoacute;n Farmacolandoacute;gica Inducida por Vancomicina","authors":"Antonio Peña-Guevara, Fern, O. Araque-Villaquiran, Jaime Sarmiento-Calderón, Diana Peñar, a-Ortega, B. López, Christian Pérez-Calvo, Nehomar Pájaro-Galvis, Jorge Rico-Fontalvo, Rodrigo Daza-Arnedo, Thalia Herrera-Calvo, María Auxiliadora Ospino-Rodríguez","doi":"10.36648/1698-9465.21.17.1457","DOIUrl":"https://doi.org/10.36648/1698-9465.21.17.1457","url":null,"abstract":"La reaccion medicamentosa con eosinofilia asociada a sintomas sistemicos, conocido como DRESS (por sus siglas en ingles Drug Reaction Eosinophilia and Systemic Syndrome), es un sindrome grave y raro que conlleva a una elevada mortalidad, asociado al uso de medicamentos, siendo mas frecuente los antibioticos, antihipertensivos y antiepilepticos. Las principales manifestaciones incluyen fiebre, erupcion morbiliforme, eosinofilia y compromiso multiorganico principalmente hepatico, no obstante, para poder corroborar su diagnostico se encuentan con escalas como el RegiSCAR. El tratamiento incluye la supresion del agente causante y uso de corticosteroides sistemicos. Describimos un caso raro de sindrome de DRESS en una mujer sometida a tratamiento con vancomicina para osteomielitis en columna vertebral con importante mejoria con el tratamiento.","PeriodicalId":44458,"journal":{"name":"Archivos de Medicina","volume":"17 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69690717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxicidad renal por tenofovir: A propósito de un caso","authors":"Javier Murgas, Camilo Andrés Pimienta Redondo, M. Jaramillo, I. T. Barragán, Felipe Herrera Ruiz, Orl, O. Castro, Elkin Arrieta Mercado, A. Caseres","doi":"10.36648/1698-9465.21.17.1484","DOIUrl":"https://doi.org/10.36648/1698-9465.21.17.1484","url":null,"abstract":"espanolEl tenofovir es un medicamento antirretroviral inhibidor de la transcriptasa inversa, que cuenta con gran efectividad, lo que se traduce en un aumento en las cifras de uso para pacientes con VIH (Virus de inmunodeficiencia humana) [1]. Pero, a pesar de tener un historial de seguridad bastante amplio y de ser un medicamento relativamente seguro y libre de eventos adversos, se han descrito en la literatura casos de falla renal aguda y tubulopatias secundarias al uso de este antirretroviral (ARV); siendo de mayor riesgo si existe un antecedente de insuficiencia renal previa en los pacientes seropositivos o cuando se emplea concomitantemente con inhibidores de la protease [2]. Por ello, se describe el siguiente caso clinico de un paciente de sexo masculino de 27 anos de edad con diagnostico final de nefropatia secundaria a la ingesta de tenofovir y atazanavir, de forma concomitante. EnglishTenofovir is a highly effective reverse transcriptase inhibitor antiretroviral drug, resulting in increased usage rates for patients with HIV (Human Immunodeficiency Virus) [1]. However, despite having a fairly broad safety record and being a relatively safe drug free of adverse events, cases of acute renal failure and tubulopathies secondary to the use of this antiretroviral (ARV) have been described in the literature; being of greater risk if there is a history of previous renal failure in seropositive patients or when it is used concomitantly with protease inhibitors, for example [2]. Therefore, the following clinical case of a 27-year-old male patient with a final diagnosis of nephropathy secondary to the concomitant ingestion of tenofovir and atazanavir is described.","PeriodicalId":44458,"journal":{"name":"Archivos de Medicina","volume":"17 1","pages":"3"},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69691561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catandaacute;strofes Tiroideas en UCI: Coma Mixedematoso y Tormenta Tiroidea. Reporte de Casos","authors":"Diana Borré Naranjo, María Cristina Martínez-Ávila, Mario Alberto Lora Andosilla, Tomás Rodríguez Yánez, Amilkar Almanza Hurtado, Carmelo Dueñas","doi":"10.36648/1698-9465.21.17.1480","DOIUrl":"https://doi.org/10.36648/1698-9465.21.17.1480","url":null,"abstract":"Las alteraciones de la funcion tiroidea son emergencias clinicas y endocrinologicas que rapidamente progresan a disfuncion organica siendo condiciones potencialmente mortal. Dentro de estos desordenes tiroideos se encuentran el coma mixedematoso siendo la manifestacion mas extrema del hipotiroidismo y la tormenta tiroidea resultante del hipertiroidismo. Las estrategias terapeuticas se basan en el rapido reconocimiento de la condicion, medidas de soporte en la unidad de cuidado critico; sin olvidar el tratamiento del factor desencadenante, con la finalidad de disminuir las complicaciones y la mortalidad.","PeriodicalId":44458,"journal":{"name":"Archivos de Medicina","volume":"17 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69691632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ciclosporina y metotrexato: Potencial alternativa de tratamiento para la COVID 19","authors":"Johan Viloria Madrid, Dilia Aparicio Marenco, J. Gómez, Maria Jose Navarro Ballestas, Jhonnier Villero Suárez","doi":"10.36648/1698-9465.21.S2.101","DOIUrl":"https://doi.org/10.36648/1698-9465.21.S2.101","url":null,"abstract":"espanolAntecedentes: Con la presentacion de la pandemia por SARS-CoV-2, existe gran incertidumbre acerca de la efectividad de los tratamientos propuestos que existen actualmente y de su efectividad para contrarrestar las manifestaciones ocasionadas por este virus o, por el contrario, exponer a los pacientes a un mayor riesgo de infeccion o en el peor de los casos, un curso mas severo de la enfermedad, ya sea de la COVID-19 o de su patologia de base. Metodologia: Se realizo una revision narrativa a traves de diversas bases de datos de octubre de 2020 a enero de 2021; la busqueda y seleccion de articulos fue llevada a cabo en revistas indexadas en idioma ingles y espanol. Se utilizaron como palabras clave: SARS- CoV-2, COVID-19, ciclosporina y metotrexato. Resultados: Metotrexato ha demostrado ser una excelente alternativa en pacientes con COVID 19 debido a su eficacia, disponibilidad, bajo precio y la amplia experiencia que se tiene de este en cuanto a su uso en la artritis reumatoide, con la finalidad de detener la respuesta inmuno-trombotica inducida por este y respaldar otras patologias asociadas a la COVID 19, como lo son las lesiones dermatologicas e inflamatorias. En cuanto a la ciclosporina se ha comprobado que la inhibicion de la via inflamatoria de calcineurina, NF-kB, utilizando ciclosporina A (CsA) produce una reduccion en la razon de probabilidades de muerte en pacientes hospitalizados afectados por COVID-19 grave. Conclusiones: La presente revision ofrece recomendaciones basadas en la evidencia disponible acerca de como la ciclosporina y metotrexato pueden llegar a convertirse en alternativa para combatir la COVID 19. EnglishBackground: With the presentation of the SARS-CoV-2 pandemic, there is great uncertainty about the effectiveness of the proposed treatments that currently exist and their effectiveness in counteracting the manifestations caused by this virus or, on the contrary, exposing them to patients are at an increased risk of infection or in the worst case, a more severe course of the disease, either from COVID-19 or its underlying pathology. Methodology: A narrative review was carried out through various databases from October 2020 to January 2021; the search and selection of articles was carried out in journals indexed in English and Spanish. The following will be used as keywords: SARS-CoV-2, COVID-19, cyclosporine and methotrexate. Results: Methotrexate has proven to be an excellent alternative in patients with COVID 19 due to its efficacy, availability, low price, and the extensive experience of this in terms of its use in rheumatoid arthritis, in order to stop the immune response -thrombotic induced by this and support other pathologies associated with COVID 19, such as dermatological and inflammatory lesions. Regarding cyclosporine, it has been proven that the inhibition of the inflammatory pathway of calcineurin, NF-kB, using cyclosporine A (CsA) produces a reduction in the probability of death ratio in hospitalized ","PeriodicalId":44458,"journal":{"name":"Archivos de Medicina","volume":"17 1","pages":"1"},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69692328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deficiencia Congénita De Factor Vii: Reporte De Caso Y Revisión De Literatura","authors":"Tito Livio Moreno, Diana Ramírez Rivera","doi":"10.36648/1698-9465.21.17.1483","DOIUrl":"https://doi.org/10.36648/1698-9465.21.17.1483","url":null,"abstract":"espanolLa deficiencia de Factor VII es un trastorno congenito poco frecuente, causado por la deficiencia del factor de coagulacion VII dependiente de vitamina K, caracterizado por niveles reducidos o ausentes de este factor que resulta en diatesis hemorragica de gravedad variable. La enfermedad se transmite de forma autosomica recesiva y la consanguinidad familiar es frecuente. Es una entidad rara por lo que describimos el primer caso diagnosticado en Honduras de paciente femenina que a los 5 dias de vida debuta con hemorragias severas en quien se constato la deficiencia de Factor VII. Paciente se encuentra con terapia sustitutiva a largo plazo con Factor VII recombinante con lo que no ha presentado hemorragias nuevamente. Para la revision del tema las referencias se identificaron mediante la busqueda en las bases de datos: Embase y PubMed. Se incluyeron articulos en ingles publicados en los ultimos 15 anos. En la redaccion del documento se usaron 19 articulos relevantes, incluyendose articulos de revision y articulos originales. EnglishFactor VII deficiency is a rare congenital disorder, caused by vitamin K dependent clotting factor VII deficiency, characterized by reduced or absent levels of this factor that results in bleeding diathesis of variable severity. The disease is transmitted in an autosomal recessive manner and family consanguinity is common. It is a rare entity, which is why we describe the first case diagnosed in Honduras of a female patient who presented with severe bleeding at 5 days of age in whom Factor VII deficiency was confirmed. Patient is on long-term replacement therapy with recombinant Factor VII, and she hasn't had new bleeding episodes. To review the topic, the references were identified by searching the databases: Embase and PubMed. Articles in English published in the last 15 years were included. In the writing of the document, 19 relevant articles were used, including review articles and original articles.","PeriodicalId":44458,"journal":{"name":"Archivos de Medicina","volume":"17 1","pages":"2"},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69691505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enfermedad Hepandaacute;tica Grasa No Alcohandoacute;lica: Perspectiva General y Riesgo Cardiovascular","authors":"Tomás Rodríguez Yánez, Almanza Hurtado Amilkar José, María Cristina Martínez Ávila, Juan Camilo Ariza, Ingrid Xiomara Tibocha Gordon, P. Acosta","doi":"10.36648/1698-9465.21.17.1481","DOIUrl":"https://doi.org/10.36648/1698-9465.21.17.1481","url":null,"abstract":"Introduccion: la enfermedad hepatica grasa no alcoholica (EHGNA) es la causa mas comun de enfermedad hepatica cronica a nivel mundial. Se considera la expresion hepatica del sindrome metabolico, los distintos componentes de este sindrome se comportan como factores potenciales de aparicion y progresion de la EHGNA; dentro de estos pacientes la enfermedad cardiovascular constituye la causa primaria de mortalidad y morbilidad. En consecuencia se ha desarrollado un interes mayor en generar estrategias que permitan impactar el efecto de la EHGNA sobre la enfermedad cardiovascular. Objetivo: evaluar la contribucion de la enfermedad hepatica grasa no alcoholica a la enfermedad cardiovascular. Metodologia: se realiza busqueda electronica en las bases de datos: PubMed, ScienciaDirect, Scopus y Medline de articulos originales y de revision en el periodo entre 1997 y 2019. Conclusion: La EHGNA es un componente fundamental del riesgo cardiovascular, constituye un elemento asociado a desenlaces cardiovasculares adversos, por lo tanto demanda un mayor interes por parte del clinico. Las opciones terapeuticas aunque variadas, distan de dar una solucion eficiente al problema metabolico desencadenado por esta condicion, siendo las estrategias no farmacologicas la piedra angular en su abordaje. Palabras clave: Enfermedad hepatica grasa no alcoholica; Esteatohepatitis no alcoholica; Elevacion de enzimas hepaticas; Sindrome metabolico; Riesgo cardiovascular","PeriodicalId":44458,"journal":{"name":"Archivos de Medicina","volume":"17 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69691600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ac-Sdkp Como Mecanismo Protector Ante La Enfermedad Valvular Aortica Fibrocalcica","authors":"Jose isidro Gomez Asis, Ricardo Antonio Rendón Muñoz, Natalia Negrete Guzman, Antonio Maria Zumaque Carrascal, luz estefany aguado torrez, A. Muñoz, Esteban de Jesús Contreras Salinas","doi":"10.36648/1698-9465.21.17.1485","DOIUrl":"https://doi.org/10.36648/1698-9465.21.17.1485","url":null,"abstract":"espanolAntecedentes: El Ac-SDKP es un tetrapeptido de origen natural con propiedades inmunomoduladores, proangiogenicas, antinflamatorias y antifibrotica. Las propiedades beneficiosas del Ac-SDKP, han generado gran interes en todo el ambito medico, acaparando unas cifras considerables de investigaciones realizadas en las ultimas dos decadas. La valvulopatia calcificante aortica es la valvulopatia mas frecuente, afectando cada vez mas a los ancianos, se caracteriza fisiopatologicamente por presentar procesos antifibroticos y antiinflamatorios. Metodologia: Se realizo una revision narrativa a traves de diversas bases de datos de Enero de 2001 a Mayo del 2021; la busqueda y seleccion de articulos fue llevada a cabo en revistas indexadas en idioma espanol e ingles. Se utilizaron como palabras clave: Ac-SDKP, Mecanismo, Protector, Valvular aortica, Fibrocalcica, IECCA. Resultados: Ac-SDKP, presenta efectos protectores ante la enfermedad valvular aortica fibrocalcica, como se demuestra en sus propiedades antifibroticas y antiinflamatorias. Dado que la calcificacion de la enfermedad esta mediada por procesos inflamatorios y procesos fibroticos, este seria un punto de partida para nuevos enfoques terapeuticos. Conclusiones: La presente revision ofrece recomendaciones para utilizar el tetrapeptido N-acetil-seril-aspartil-lisil-prolina (Ac-SDKP) como punto de partida para nuevos enfoques terapeuticos. EnglishBackground: Ac-SDKP is a naturally occurring tetrapeptide with immunomodulatory, proangiogenic, anti-inflammatory and antifibrotic properties. The beneficial properties of Ac-SDKP have generated great interest throughout the medical field, accounting for considerable amounts of research carried out in the last two decades. Calcifying aortic valve disease is the most common valve disease, increasingly affecting the elderly, it is pathophysiologically characterized by presenting antifibrotic and antiinflammatory processes. Methodology: A narrative review was carried out through various databases from January 2001 to May 2021; the search and selection of articles was carried out in journals indexed in Spanish and English. The following keywords were used: Ac-SDKP, Mechanism, Protector, Aortic valve, Fibrocalcic, IECCA. Results: Ac-SDKP has protective effects against fibrocalcic aortic valve disease, as demonstrated by its antifibrotic and anti-inflammatory properties. Given that the calcification of the disease is mediated by inflammatory processes and fibrotic processes, this would be a starting point for new therapeutic approaches. Conclusions: This review offers recommendations to use the N-acetyl-serylaspartyl-lysyl-proline tetrapeptide (Ac-SDKP) as a starting point for new therapeutic approaches.","PeriodicalId":44458,"journal":{"name":"Archivos de Medicina","volume":"31 1","pages":"4"},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69691620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Absceso Cerebral: Una Revisiandoacute;n de la Literatura","authors":"Jorge Yepez-Caro, Christian Pérez-Calvo, Indira Lambertinez-Alvarez, Nehomar Pájaro-Galvis, Daniela Arrieta-Segura, Daniela Hurtado-Meza, M. Martinez-Viloria, Yuranis Navarro-Álvarez, Fabio Perez-Contreras, Andrea Pestana Mir, Jorge-Eduardo Rico-Fontalvo, Ana Obeso-Torres","doi":"10.36648/1698-9465.21.17.1467","DOIUrl":"https://doi.org/10.36648/1698-9465.21.17.1467","url":null,"abstract":"Introduccion: El absceso cerebral se define como un proceso supurativo focal del parenquima cerebral, que, a pesar de su incidencia relativamente baja, constituye un problema de salud mundial, por su alta morbimortalidad y carga economica para el sistema de salud. Afortunadamente, la mortalidad por esta causa ha disminuido notoriamente gracias a la introduccion de los estudios de imagenes que permiten hacer un diagnostico temprano y un tratamiento oportuno. Objetivo: Revisar los conceptos de epidemiologia, etiologia, fisiopatologia, diagnostico, tratamiento y complicaciones del absceso cerebral segun la evidencia actual disponible. Metodologia: Las referencias se identificaron mediante la busqueda en las diferentes bases de datos: PubMed, MEDLINE, EBSCO host, SCIENCE DIRECT, OvidSP y en las plataformas de las Revistas Lancet y New England Journal of Medicine. La busqueda se limito a los idioma ingles y espanol, publicados en los ultimos 10 anos, sin embargo, se anadieron algunos articulos que sobrepasan este periodo, pero que son claves para el tema tratado. Resultados: Se recolectaron 148 articulos, de los cuales para la redaccion del documento se usaron 33 articulos a conveniencia, incluyendose articulos de revision, metaanalisis y articulos originales. Conclusiones: El absceso cerebral es una enfermedad potencialmente mortal, cuyo pronostico depende de un diagnostico y manejo tempranos con intervencion de un equipo multidisciplinario. Las manifestaciones clinicas suelen ser inespecificas por lo que la identificacion de la entidad depende de estudios de neuroimagen. Finalmente, el tratamiento asocia manejo medico con antibioticoterapia e intervencion neuroquirurgica para drenaje del foco.","PeriodicalId":44458,"journal":{"name":"Archivos de Medicina","volume":"17 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69690654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}